Summary of findings for the main comparison. Resistance testing versus no resistance testing in HIV‐positive people.
Resistance testing versus no resistance testing in HIV‐positive people | ||||||
Patient or population: HIV‐positive people Setting: all settings Intervention: resistance testing Comparison: no resistance testing | ||||||
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Number of participants (trials) | Certainty of the evidence (GRADE) | Comments | |
Risk with no resistance testing | Risk with resistance testing | |||||
Mortality | Study population | OR 0.89 (0.36 to 2.22) | 1140 (5 RCTs) | ⊕⊕⊕⊝
MODERATEa,b,c Due to imprecision |
Resistance testing probably has little or no impact on mortality | |
22 per 1000 | 20 per 1000 (8 to 47) | |||||
Virological failure | Study population | OR 0.70 (0.56 to 0.87) | 1728 (10 RCTs) | ⊕⊕⊝⊝
LOWa,d,e,f Due to risk of bias and publication bias |
Resistance testing may reduce the risk of virological failure | |
660 per 1000 | 576 per 1000 (521 to 628) | |||||
Change in CD4 cell count | Mean change in CD4 cell count was 0. | MD 1 lower (12.49 lower to 10.5 higher) | ‐ | 1349 (7 RCTs) | ⊕⊕⊕⊝
MODERATEa,d Due to risk of bias |
Resistance testing probably has little or no effect on change in CD4 cell count |
Progression to AIDS | Study population | OR 0.64 (0.31 to 1.29) | 809 (3 RCTs) | ⊕⊕⊕⊝
MODERATEg Due to indirectness |
Resistance testing probably has little or no impact on progression to AIDS | |
67 per 1000 | 44 per 1000 (22 to 85) | |||||
Adverse events | Study population | OR 0.89 (0.51 to 1.55) | 808 (4 RCTs) | ⊕⊕⊝⊝
LOWh,i Due to risk of bias and indirectness |
Resistance testing may have little or no effect on adverse effects | |
74 per 1000 | 66 per 1000 (39 to 110) | |||||
Change in viral load | Mean change in viral load was 0. | MD 0.23 lower (0.35 lower to 0.11 lower) | ‐ | 1837 (10 RCTs) | ⊕⊕⊕⊝
MODERATEa,j Due to risk of bias |
Resistance testing probably results in a lower viral load |
Quality of life ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
New opportunistic infection ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Abbreviations: CI: confidence interval; MD: mean difference; OR: odds ratio; RCT: randomized controlled trial | ||||||
GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect |
aRisk of bias: all studies included for this outcome were not blinded, but we did not downgrade for this, as lack of blinding is unlikely to introduce bias. bRisk of bias: one included study was at high risk of bias overall, but it contributed 16.1% of the data (Wegner 2004). We did not downgrade for this. cDowngraded by 1 for imprecision: CIs for the odds ratio include considerable harm and considerable benefit. We downgraded one point for this. dDowngraded by 1 for risk of bias: four of the included studies (˜ 37% of data) were at high or unclear risk of bias (Cingolani 2002;Cohen 2002;Haubrich 2005;Rubini 2002). eIndirectness: the included studies used different cutoffs to define virological failure. We did not downgrade for this. fDowngraded by 1 for publication bias: based on funnel plot asymmetry and a positive Egger's test. gDowngraded by 1 for indirectness: "progression to AIDS" was not defined uniformly across studies. hDowngraded by 1 for risk of bias: all studies included for this outcome were not blinded and adverse events could be interpreted subjectively. iDowngraded by 1 for indirectness: "adverse event" was not defined uniformly across studies. We downgraded one point for this. jDowngraded by 1 for risk of bias: four of the included studies (˜ 34% of data) were at high or unclear risk of bias (Cingolani 2002;Cohen 2002;Haubrich 2005;Rubini 2002).